U.S. Markets closed

LIBERTY HEALTH SCIENCES INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Liberty Health Sciences Inc.

Lead Plaintiff Deadline is March 9, 2019

NEW YORK, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased or otherwise acquired Liberty Health Sciences Inc. (“Liberty” or the “Company”) (OTC: LHSIF; XCNQ: LHS) securities between June 28, 2018 and December 3, 2018, inclusive (the “Class Period”).

Shareholders who purchased shares of Liberty Health Sciences Inc. and suffered losses on United States and/or Canadian exchanges are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If you have incurred losses in the shares of Liberty Health Sciences Inc., you may, no later than March 9, 2019, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in March 9, 2019.

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

The filed complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that:

  • Liberty, in conjunction with Aphria, was involved in a scheme whereby numerous fraudulent acquisitions and transactions were made to provide undue benefits to both companies’ insiders; and
     
  • as a result, Liberty’s public statements were materially false and misleading at all relevant times.

In September 2018, Liberty sold its stake in Aphria Inc. (“Aphria”). On December 3, 2018, Quintessential Capital Management and Hindenburg Research issued a report entitled “Aphria: A Shell Game with a Cannabis Business on the Side,” claiming that Aphria was part of a scheme orchestrated by a network of insiders to divert funds away from shareholders and into their own pockets.

On this news, Liberty’s stock price fell $0.36 per share, or nearly 34%, over the next two trading days to close at $0.70 on December 4, 2018, thereby injuring investors.

Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.